RGT Stock Overview
A multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Argent BioPharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.25 |
| 52 Week High | AU$0.70 |
| 52 Week Low | AU$0.15 |
| Beta | 1.08 |
| 11 Month Change | -23.08% |
| 3 Month Change | -28.57% |
| 1 Year Change | -64.54% |
| 33 Year Change | -99.43% |
| 5 Year Change | -99.26% |
| Change since IPO | -99.83% |
Recent News & Updates
Shareholder Returns
| RGT | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -12.3% | -16.4% | 0.9% |
| 1Y | -64.5% | 32.2% | 18.4% |
Return vs Industry: RGT underperformed the Australian Pharmaceuticals industry which returned 35% over the past year.
Return vs Market: RGT underperformed the Australian Market which returned 17.7% over the past year.
Price Volatility
| RGT volatility | |
|---|---|
| RGT Average Weekly Movement | 21.6% |
| Pharmaceuticals Industry Average Movement | 11.8% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: RGT's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: RGT's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Roby Zomer | argentbiopharma.com |
Argent BioPharma Limited, a multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. The company’s principal product candidates include CimetrA, which is in phase IIB clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and RGAI03MW01, which focuses on chronic wound treatment.
Argent BioPharma Limited Fundamentals Summary
| RGT fundamental statistics | |
|---|---|
| Market cap | AU$13.57m |
| Earnings (TTM) | -AU$17.53m |
| Revenue (TTM) | AU$891.08k |
15.2x
P/S Ratio-0.8x
P/E RatioIs RGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGT income statement (TTM) | |
|---|---|
| Revenue | AU$891.08k |
| Cost of Revenue | AU$1.20m |
| Gross Profit | -AU$304.15k |
| Other Expenses | AU$17.23m |
| Earnings | -AU$17.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | -34.13% |
| Net Profit Margin | -1,967.34% |
| Debt/Equity Ratio | -149.0% |
How did RGT perform over the long term?
See historical performance and comparison